Clinical trials: OHT - Ocular Hypertension
Glaucoma
OculusGen-Glaucoma Historical Control Study in Taiwan
The purpose of this study is to determine whether the OculusGen Collagen Matrix are effective and safe to implant as an aid of glaucoma surgery.
- Trial name
- NCT00406822
- Testing
- OculusGen Biodegradable Collagen Matrix Implant
- Where
- Taiwan
- Volunteers
- 48 people
- Sponsor
- Pro Top & Mediking Company Limited
Glaucoma, Ocular Hypertension
Effects of Travatan Z and Xalatan on Ocular Surface Health
The purpose of this randomized, double-masked, parallel-group, multicenter study is to evaluate ocular surface effects after the administration of travoprost with SofZia® preservative system or Xalatan once daily for 12 weeks.
- Trial name
- NCT00708422
- Testing
- Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®), Latanoprost ophthalmic solution 0.005% (XALATAN®)
- Volunteers
- 231 people
- Sponsor
- Alcon Research
Glaucomas, Pterygium
Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Zhong-Shan Hospital
The purpose of this study is to determine whether the OculusGen Collagen Matrix are effective and safe to implant as an aid of glaucoma surgery.
- Trial name
- NCT00320957
- Testing
- OculusGen Biodegradable Collagen Matrix Implant
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Pro Top & Mediking Company Limited
Glaucoma, Ocular Hypertension
Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study will investigate the safety and efficacy of Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution in patients with glaucoma or ocular hypertension who have elevated…
- Trial name
- NCT01284166
- Testing
- dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution
- Sponsor
- Allergan
Glaucoma, Open Angle or Ocular Hypertension
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic suspension 1%) dosed three times daily in IOP…
- Trial name
- NCT01722604
- Testing
- brinzolamide 1% ophthalmic suspension, Azopt 1%
- Where
- United States
- Volunteers
- 258 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Hypertension, Glaucoma
Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or…
- Trial name
- NCT00809848
- Testing
- AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
This efficacy and safety study will evaluate LUMIGAN® RC/ LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL MALEATE-EX, 0.5%/TIMOLOL GFS 0.5% (timolol 0.5% ophthalmic gel forming…
- Trial name
- NCT01881126
- Testing
- bimatoprost 0.01%, travatan 0.004%, timolol 0.5%
- Where
- 2 sites in Canada
- Volunteers
- 93 people
- Sponsor
- Allergan
Primary Open-angle Glaucoma
Long-term Safety and Performance of the ARGOS-IO Intraocular Pressure Sensor System in Subjects With Primary Open Angle Glaucoma (POAG)
The purpose of this study is to evaluate the long-term safety and performance of the ARGOS-IO system in patients with Primary Open Angle Glaucoma (POAG)
- Trial name
- NCT03651336
- Testing
- ARGOS-IO Sensor Pressure System
- Where
- 4 sites in Germany
- Volunteers
- 16 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Glaucoma
Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Trial name
- NCT07075718
- Testing
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma
Study of Exchange of Travoprost Intraocular Implant
The study objective is to evaluate the safety of the operative and surgical exchange procedure of Travoprost Intraocular Implant in subjects with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT04615403
- Testing
- Travoprost
- Where
- 14 sites in United States, Philippines
- Volunteers
- 33 people
- Sponsor
- Glaukos Corporation
Glaucoma, Cataract
Comparative Study of the Cornea/Anterior Segment OCT CASIA2 and the RTVue XR OCT Avanti With AngioVue Software
This study is a prospective comparative, randomized, single center study to gather agreement and precision data in all subjects.
- Trial name
- NCT04486976
- Testing
- Cornea/Anterior Segment OCT CASIA2, Optovue RTVue XR Avanti
- Where
- United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Tomey Corporation
Glaucoma, Open-Angle, Ocular Hypertension
Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.
Phase IV randomized, double blind, multicenter, parallel group clinical study to evaluate the efficacy of the combined use of Krytantek Ofteno PF® and Gaap Ofteno PF®, both applied every 12 hours, versus the use of Eliptic Ofteno…
- Trial name
- PRO-122 (NCT04702789)
- Testing
- Dorzolamide-timolol-brimonidine and latanoprost, Dorzolamide-timolol and latanoprost
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Primary Open Angle Glaucoma, Pigmentary Glaucoma
Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study
The study objective is to demonstrate the safety of Minimally Invasive Micro Sclerostomy (MIMS) device for lowering elevated IOP in patients diagnosed with glaucoma.
- Conditions
- Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
- Trial name
- NCT02355990
- Testing
- Minimally Invasive Micro Sclerostomy
- Where
- Israel
- Volunteers
- 96 people
- Sponsor
- Sanoculis Ltd
Primary Open Angle Glaucoma of Both Eyes
Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml
The goal of this study is to compare efficacy and safety of Dorzol 20 mg/mL Eye Drops manufactured by JADRAN-GALENSKI LABORATORIJ d.d.
- Trial name
- NCT05973305
- Testing
- Dorzol 20 mg/ml, Trusopt 20 mg/ml
- Where
- Russia
- Volunteers
- 118 people
- Sponsor
- Jadran Galenski laboratorij d.d.
Ocular Hypertension, Glaucoma
A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients
The purpose of this study is to demonstrate that fixed combination of latanoprost and timolol (PhXA41) has better IOP lowering effect than the individual monotherapies.
- Conditions
- Ocular Hypertension, Glaucoma, Open-angle Glaucoma
- Trial name
- NCT00856622
- Testing
- i. Fixed combination of latanoprost 0.005% and timolol 0.5%, timolol 0.5% ophthalmic solution, latanoprost 0.005% ophthalmic solution
- Where
- 37 sites in Germany
- Volunteers
- 436 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Ocular Hypertension
Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution
- Trial name
- NCT06394973
- Testing
- T4090 0.2%, T4090 0.3%, Rhopressa®
- Where
- 24 sites in United States
- Volunteers
- 161 people
- Sponsor
- Laboratoires Thea
Glaucoma, Open-Angle, Ocular Hypertension
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00051142
- Testing
- Travoprost, Latanoprost
- Where
- United States
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma, Ocular Hypertension
Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.
- Trial name
- NCT04747808
- Testing
- LL-BMT1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- MediPrint Ophthalmics, Inc.
Glaucoma
Glaucoma HFA / OCT Specificity Study
Study consists of five visits over a one to three month time period.
- Trial name
- NCT02708082
- Testing
- OCT scanning and HFA perimetry
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Carl Zeiss Meditec, Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 3 Study Comparing the Efficacy and Safety of Netarsudil Ophthalmic Solution 0.02% QD to Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% BID, for Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension…
- Trial name
- NCT04620135
- Testing
- Netarsudil ophthalmic solution 0.02%, Ripasudil hydrochloride hydrate ophthalmic solution 0.4%
- Where
- Japan
- Volunteers
- 245 people
- Sponsor
- Aerie Pharmaceuticals